Sector News

Valeant's Bausch + Lomb plant getting $150M in investments, up to 200 jobs

October 15, 2015
Life sciences

Valeant Pharmaceuticals has been pumping out a lot of products at its Bausch + Lomb plant in South Carolina, reaching the 4 billion bottle mark this week.

The company marked the occasion by announcing plans to invest in expansions that will add as many as 200 jobs over 5 years.

Valeant CEO J. Michael Pearson showed up at the plant, which manufactures products that include the Boston and ReNu lines of contact lens solutions, to share the news. According to the announcement, the company will make an immediate investment of about $25 million to add an another line at the facility. Coupled with earlier investments in the facility, the expansion will allow the plant to add another 40 million units, a 20% production boost. That will also lead to hiring another 30 employees to the 500 person workforce. The Canadian-based company will receive incentives that include a property tax break on the expansion.

But there will be more in coming years, Pearson told employees. The company is looking to invest approximately $90 million over the next two years, and about $150 million over the next 5. If realized, those investments will mean the need for another 150 to 200 workers.

Pearson said that reaching the 4-billion bottle milestone was a testament to the “enormous impact that the facility has had across the globe.” Valeant bought the company in 2013, paying investment firm Warburg Pincus $4.5 billion and spending another $4.2 billion to pay the company’s outstanding debt.

Not everything was as upbeat this week for Pearson. The company Thursday acknowledged receiving subpoenas from two different offices of the U.S. Attorney seeking info on price hikes. The company has found itself on a hot seat with members of Congress who want explanations for Valeant’s decision to jack up the prices of its drugs this year an industry-leading average of 65.6%. They are particularly interested in hearing about two drugs, Isuprel and Nitropress, for which Valeant increased the prices 525% and 212%, respectively.

By Eric Palmer

Source: Fierce Pharma Manufacturing

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach